FLCCC | Front Line COVID-19 Critical Care Alliance
FLCCC | Front Line COVID-19 Critical Care Alliance
Donate
Latest Updates

FLCCC Responds to WSJ Article on TOGETHER Trial

Published On: March 18, 2022|
Print Friendly, PDF & Email

On March 18, 2022, The Wall Street Journal published an article entitled: ‘Ivermectin Didn’t
Reduce Covid-19 Hospitalizations in Largest Trial to Date’.

The results of this trial, which was predetermined to show ivermectin as ineffective, affirms the
need for early treatment against COVID-19 and confirms that conflicted groups continue to
influence competitor trials, ensuring they are designed to fail. Several organizations associated
with the trial have a paid client relationship with Pfizer, which has secured Federal government
contracts worth $5.3 billion for its antiviral treatment, Paxlovid. A full list of trial sponsors and
associates can be found here.

It is therefore no surprise that the trial was designed to fail. In the medical community, it is
common knowledge that COVID-19 becomes far more difficult to treat the longer a patient has
had symptoms. Treating early is imperative. Yet the TOGETHER trial studied patients where
they started treatment up to eight days after the onset of symptoms.
Furthermore, no qualified physician or scientist recommends treating COVID-19 with the low
dosage of ivermectin used in the trial, nor treating a patient with ivermectin for only three days
on an empty stomach, as TOGETHER did. FLCCC physicians have understood for nearly 18
months that ivermectin works best against COVID-19 when administered with a fatty meal and
until symptoms resolve.

Our frontline physicians – who were treating COVID-19 with corticosteroids months before the
NIH recommended them – have found ivermectin is most effective as part of a treatment protocol
that includes other FDA-approved medications and supplements backed by clinical and
observational evidence. The use of our I-MASK+, MATH+ and I-RECOVER protocols have all
been proven to be effective at corresponding stages of the illness.

Trials of generic medicines that are funded and influenced by profit-driven pharmaceutical
companies will always fail. We need to create an independent, well-funded government body
dedicated to conducting well-designed trials and transparent research studies of repurposed
generic treatments – not only for COVID-19, but for all diseases that may have safe and
affordable remedies. The use of independent research is our only hope of understanding how
these medicines can best be used to help patients.
##

Explore Similar Stories

Title

Go to Top